Сравнение
Retatrutide vs. VK2735
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
2381089-83-2
нет данных
Молекулярная масса
4731.6 g/mol
нет данных
Период полувыведения
144 h
нет данных
Последовательность
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSнет данных
Механизм действия
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
VK2735
VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
1
из них на людях
4
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
2
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Retatrutide and VK2735?
- Retatrutide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Retatrutide or VK2735?
- The highest available evidence level is "РКИ на людях" for Retatrutide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Retatrutide and VK2735 in Germany and the United States?
- Германия: Retatrutide — Не одобрено, VK2735 — Не одобрено. США: Retatrutide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.